



ABIVAX – 2015 Half-Year Results - €57.7 million raised on Euronext and significant clinical progress on chronic Hepatitis B and HIV/AIDS

September 29, 2015

- €57.7 million raised, covering the company's net financial needs through the end of 2017
- Strong acceleration in the company's clinical development program with the launch in early 2015 of the ABVX203 pivotal trial (Phase IIb/III) to address chronic Hepatitis B, and the first phase IIa study on ABX464 for the treatment of HIV/AIDS
- Pioneering partnerships with Cuban life sciences organizations have been strengthened.